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An infectious raccoon poxvirus (RCNV) was used to express the feline panleukopenia virus (FPV) open reading frame
VP2. The recombinant, RCNV/FPV, was constructed by homologous recombination with a chimeric plasmid for inserting
the expression cassette into the thymidine kinase (TK) locus of RCNV. Expression of the VP2 DNA was regulated by the
vaccinia virus late promoter P11 . Southern blot and polymerase chain reaction (PCR) analyses confirmed the cassette was
in the TK gene of the RCNV genome. An immunofluorescent antibody assay using feline anti-FPV polyclonal serum showed
the expressed viral antigen in the cytoplasm of infected cells. Radioimmunoprecipitation with the same antiserum detected
a 67-kDa VP2 protein which exactly matched the migration of the authentic FPV VP2 protein by SDS–polyacrylamide gel
electrophoresis. Nine five-month-old cats were vaccinated and 21 days later were boosted with the recombinant virus.
Peroral FPV challenge 2 weeks after the booster showed that the cats were fully protected as measured by examining
clinical signs and total white blood cell counts in peripheral blood. Cats not immunized developed low to very low leukocyte
counts following peroral FPV challenge. The nine vaccinated cats showed high FPV neutralization antibody prior to challenge,
whereas nonvaccinated cats formed anti-FPV antibodies only after challenge. q 1996 Academic Press, Inc.
Feline panleukopenia virus (FPV) causes severe clinical VP2 protein which is converted to a 60- to 64-kDa poly-
peptide (VP3) by proteolytic cleavage to remove 15 to 20illness in young kittens with high morbidity and mortality
amino acids. Empty viral particles propagated in vitro or(1–3). Because the replication of FPV requires rapidly multi-
in vivo contain mostly VP2, a few VP1 subunits, and noplying cells, the lesions caused by FPV are mainly found
VP3 (9, 10). Intact virions contain the three proteinsin tissues with the greatest rate of mitotic activity, such as
nested to include the viral DNA (11, 12). Infectious CPVin bone marrow (1, 2). Clinically, a marked drop in total
particles contain 60 subunits of protein that is predomi-leukocyte count by Days 4 to 6 after infection is the predom-
nantly VP2.inant indicator of FPV infection (2–4).
Structure analysis of CPV particles has revealed thatFPV is closely related to canine parvovirus (CPV) and
part of the amino terminal region of VP2 is on the exteriormink enteritis virus at the protein and nucleic acid levels
of the virion and is associated with immunodominant(5, 6). The complete genomic DNA sequences of FPV
antigenic epitopes (13). Certain residues on the extremeand CPV have been determined. The sequences reveal
outside of the CPV particles are in common with residuesthat there are only 50 nucleotide differences between
on FPV particles (13). Because the amino terminal of VP1the two viruses (7). The host range differences between
is unusually basic, it might help neutralize the DNA (14).the two viruses were found in the DNA region of 59–73
Antisera against FPV and CPV have shown very similarmap units (7, 8). The genome of FPV is a linear, single-
antibody titers against either virus by virus neutralizationstranded DNA of about 5,000 nucleotides that encodes
(VN) and hemagglutination-inhibition tests (5, 8, 15).three structural proteins: a large 80- to 85-kDa protein
Based on the close similarities between CPV and FPV,(VP1) composing 10 to 15% of the virion protein, a me-
it has been speculated that the vaccines developed withdium size 64- to 67-kDa protein (VP2), and a part of the
either virus will protect against both feline and canine
parvovirus infections (16). Finally, the structural proteins,
VP1 and VP2 of Aleutian mink disease parvovirus (ADV),1 Present address: Division of Comparative Medicine, Johns Hopkins
have been produced in a baculovirus expression system;University, School of Medicine, Baltimore, MD 21205.
2 To whom correspondence and reprint requests should be ad- the expressed proteins self-assembled as empty parti-
dressed. Fax: (607) 253-3419. cles (17).
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Raccoon poxvirus (RCNV) is an orthopoxvirus; two iso- cleotides 516–535) and GATCACCATCTGCTGGTTGA
(VP2 ORF nucleotides 1627–1608) were utilized to iden-lates were derived from upper respiratory tissue of two
apparently healthy raccoons trapped in Maryland in 1964 tify satisfactory recombinant viral plaques. The VP2 ORF
sequences were detected in lysates of virus-infected(18). A comparative study with several different poxviruses
has indicated that RCNV inoculation of cats induces higher cells by dot-blot hybridizations, and in recombinant viral
genome DNA by detecting PCR amplified VP2 ORF inter-autologous VN antibody titer than autologous antibodies
induced by other poxviruses tested (19). Laboratory animal nal sequences in thrice plaque-purified, phenol-chloro-
form-extracted, recombinant viral genome DNA prepara-studies with a RCNV rabies virus glycoprotein recombinant
(RCN-G) have indicated that oral administration of RCN-G tions (data not shown). The recombinant virus isolate
replicated in Rat-2 cells under BUDR and formed typicalinduces rabies VN antibodies and protection against rabies
challenge in raccoons and in a variety of other animals RCNV plaques. The results suggested to us that the in-
serted VP2 ORF was located in the TK locus of the RCNVtested (20). In cats vaccinated perorally, RCN-G has been
genome. Production of the recombinant virus confirmedshown to induce rabies virus VN antibodies and not spread
also that VV TK insertion vectors such as pTKgptF3S canto cats in contact with vaccinated cats (16). Earlier, it had
be directly used for foreign gene insertion into the RCNVbeen shown that the thymidine kinase (TK) gene fragment
TK locus (20, 21).of RCNV was able to cross-hybridize with that of vaccinia
virus (VV), and this enabled construction of RCNV recombi- The in vitro expression of VP2 protein by recombinant
RCNV/FPV was demonstrated by indirect immunofluores-nants with various chimeric plasmids designed for foreign
gene expression by marker rescue into the VV TK locus cent antibody (IIFA) and radioimmunoprecipitation (RIP)
tests as shown in Figs. 1 and 2. In the IIFA test, RCNV-(20–22).
infected CrFK cells (Fig. 1a) and mock-infected CrFK cellsIn the present study, an infectious RCNV FPV VP2 re-
(not shown) did not react with anti-FPV antibodies. FPV-combinant (RCNV/FPV) was developed by recombining
infected CrFK cells showed intranuclear fluorescencea FPV VP2 expression cassette into the TK locus of the
(Fig. 1b); however, RCNV/FPV-infected CrFK cell mono-RCNV genome. To generate the recombinant, the FPV
layers showed VP2 antigen in the cytoplasm (Fig. 1c).VP2 open reading frame (ORF) in 2304 bp excised from
The FPV polyclonal antiserum used in our experimentsa FPV infectious clone was inserted into the plasmid
is a standard diagnostic serum that does not cross-reactpTKgptF3S (23). The first 33 bases of the ORF were de-
with RCNV or feline viruses generally tested for in veteri-leted by HincII digestion and the remaining DNA frag-
nary clinics.ment was inserted under control of the VV P11 late pro-
moter in pTKgptF3S. Southern blot analysis followed by The infection and replication cycle of orthopoxviruses,
including raccoon poxvirus, occurs completely in the cy-sequencing with a CTACTTGCATAGATAGGT primer, de-
signed to anneal 167 bases up from a start codon at the toplasm (27). Consistent with this, the VP2 protein ex-
pressed by RCNV/FPV under promoter P11 appears inend of the P11 late promoter, enabled selection of an
appropriate chimeric plasmid (not shown) for developing the cytoplasm during the late infection stage. Interest-
ingly, ADV structural proteins VP1 and VP2 coexpressedrecombinant RCNV. Thus, pTKgptF3S containing the left-
end of the VV TK followed by TAAAAATATAGTAGAATT- in a baculovirus expression system have been shown to
be empty particles in the nucleus of baculovirus recombi-TCATTTTGTTTTTTTCTATGCTATAAATGAATTCCTGC-
AGGTCAACCTGCTGTCA and the remainder of VP2 nant-infected insect cells (17). During authentic FPV in-
fection, VP1 and VP2 also appear in the nucleus, mainlysequences to the stop codon was selected for further
analysis (note: nucleotides to the left of the ATG (bold in virus particles. Because we expressed only FPV VP2,
we did not examine RCNV/FPV-infected cells for emptyfont) are P11 late promoter sequences; nucleotides to the
right of the ATG are the in-frame bases of the VP2 ORF FPV particles. The reason why the VP2 transcription
product in RCNV/FPV-infected cells is not transported tofrom a HincII site in a polylinker sequence that remained
after cloning). the nucleus is unclear. However, the marked shut down
of host cell protein synthesis by the late time of RCNV/Infectious RCNV recombinants carrying the VP2 ORF
FPV infection and/or lack of other coexpressed FPV com-were obtained by transfecting the chimeric plasmid into
ponents, e.g., VP1, might be responsible.CV-1 cell monolayers that had been infected for 2 hr with
RCNV by methods described elsewhere (20, 22, 24–26). RIP of [ 35S]methionine pulse-labeled proteins in ly-
sates of cells infected with RCNV/FPV or RCNV alsoRat-2 TK minus cells were then used to select RCNV
recombinant viruses by thrice plaque-purifying in the showed that VP2 protein is expressed by RCNV/FPV and
that VP2 is recognized by FPV antibodies (Fig. 2). Fourpresence of 50 mg 5-bromo-2*-deoxyuridine (BUDR)/ml
of medium. Dot-blot hybridizations with a VP2 DNA probe plaque-purified RCNV/FPV recombinant preparations
that we made expressed VP2 protein when examined byand PCR amplifications of VP2 ORF internal sequences
with primers AGTTCAACCAGACGGTGGTC (VP2 ORF nu- 8 to 25% gradient gel SDS–PAGE. The expressed protein
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migrated at 67 kDa (lanes 1–4), which is the same as
reported (9, 10, 13) for mature VP2 protein from FPV-
infected cells. The 67-kDa protein did not appear in ly-
sates of cells infected with RCNV (lane 5) or mock-in-
fected cell lysates (not shown).
Specific recognition of VP2 protein by FPV polyclonal
antiserum in IIFA and RIP assays suggested to us that
FIG. 2. Radioimmunoprecipitation detection of FPV VP2 expressed
by RCNV/FPV. CV-1 cell monolayers were infected with the RCNV/FPV
or RCNV and then incubated at 377 for 1 hr in methionine-free medium
followed by pulse-labeling for 16 hr at 377 in medium containing 500
mCi [ 35S]methionine. The cells were washed and then lysed in a buffer
containing 100 mM NaCl, 50 mM Tris–HCl, pH 8.0, 5 mM Na2EDTA,
1% Triton X-100, 1% deoxycholic acid, and 50 mM phenylmethylsulfonyl
fluoride. The lysate was then incubated overnight at 47 with cat anti-
FPV serum. Protein A–Sepharose was then added to the antibody–
lysate mixture and incubated and agitated for 2 hr at room temperature.
The complex was washed by centrifugation and finally dissolved and
heated for 3 min at 1007 in loading buffer for a 8–25% SDS–PAGE
gradient PhastGel (Pharmacia Biotech, Sweden). After electrophoresis
in the Phastsystem Separation and Control Unit, the gel was fluorogra-
phed and then exposed to the X-ray film to detect 35S-labeled proteins.
Lanes 1–4 show precipitates from four separate plaque-purified recom-
binant-infected cell lysates of CV-1 cells infected with RCNV/FPV; pro-
tein migrating at 67 kDa is apparent; lane 5 shows lack of a precipitated
homolog from a lysate of CV-1 cells infected with RCNV.
the protein expressed by RCNV/FPV is structurally satis-
factory for appropriate immunogenic determinants of
VP2. Consistent with the data here, in a related study,
an FPV VP2 monoclonal antibody identified the same
expressed VP2 protein in another RCNV construct that
coexpresses FPV VP2 and the rabies virus glycoprotein
(Hu et al., unpublished data).
The immune response of nine 5-month-old cats to vac-
cination with the RCNV/FPV was examined by subcuta-
neous (SQ) inoculation with the recombinant followed by
a booster 21 days later. The vaccinated cats and two
unvaccinated cats were challenged by using the USDA
standard FPV challenge method (28) on Day 34 after
primary vaccination. In Fig. 3 we show that following the
initial vaccination with RCN/FPV, the geometric mean
serum VN antibody titer of the nine vaccinated cats had
FIG. 1. Indirect immunofluorescent FPV antibody reactivity of CrFK reached 1:1,000 by Day 21, the day on which the cats
cells infected with RCNV, FPV, or RCNV/FPV virus. CrFK cell monolayers were boosted. Seven days after the booster, the mean
in 8-well LabTek chamber slides (Nunc, Inc., IL) were infected with 10
serum VN antibody titer was 1:5,000. Thirteen days afterPFU per cell of RCNV, FPV, or RCNV/FPV. After 24 hr incubation, the
booster, the mean VN titer was still 1:5000; however, bycells were acetone-fixed, blocked with normal rabbit serum, and then
incubated with feline FPV polyclonal antiserum followed by washing 22 days after the booster the titer was determined to be
and incubation with fluorescein-conjugated rabbit anti-cat IgG. (a) This 1:17,500. No FPV VN antibodies were detected in cats
panel shows CrFK cell monolayer infected with RCNV does not react not vaccinated.
with the anti-FPV serum; (b) shows a CrFK cell infected with FPV re-
Challenge of the vaccinated cats with FPV on Day 13acted with anti-FPV serum and immunofluorescence was mainly in the
after the booster did not raise the VN antibody level,nucleus; (c) shows a CrFK cell infected with RCNV/FPV reacted with
anti-FPV serum and immunofluorescence was mainly in the cytoplasm. suggesting that challenge virus replication was stopped
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by vaccination with RCNV/FPV. On the other hand, unvac-
cinated animals showed detectable VN titers at Day 5
after FPV challenge. The appearance of circulatory FPV
antibodies is consistent with development of a humoral
response to infection during challenge. In a separate
study (16) with RCNV/FPV at a higher dose in older cats
less susceptible to FPV, a single vaccination also
showed a significant VN antibody response and protec-
tion of cats from FPV challenge.
We have not yet examined the cell-mediated immune
response after RCNV/FPV vaccination; however, we
speculate that such a response is also playing an active
role in providing protection from FPV challenge. In other
candidate parvovirus vaccine systems that do not use a
recombinant that replicates in the vaccinated animal,
e.g., peptide vaccines and baculovirus systems, it is likely
that cell-mediated immunity levels are low or not pro-
duced.
FIG. 4. Geometric mean of the total white blood cell (WBC) countsTotal white blood cell and differential counts were
in peripheral blood samples taken after FPV challenge of vaccinatedmeasured on Days 0, 3, 5, 9, and 20 following FPV chal-
and nonvaccinated cats. The nine RCNV/FPV vaccinated cats and thelenge. Fig. 4 shows that the nine vaccinated cats had
two mock-vaccinated cats challenged with 104.7 TCID50 FPV perorally
total white blood cell counts within a normal range of 13 days after booster according to a USDA standard procedure (28).
6.1–21.1 1 103/ml throughout the vaccination and chal- The total and differential WBC were determined from blood samples
taken on Days 0, 3, 5, 9, and 20 after challenge. Total WBCs on Daylenge. Also, counts of lymphocytes, monocytes, eosino-
0 were considered to be the normal level for the individual cat. The WBCphils, and basophils remained within normal ranges
counts were determined using a quantitative automated hematology
analyzer (Coulter Counter Model S Plus IV, Coulter Corporation, Hia-
leah, FL). The dark squares with standard deviation indicate the geo-
metric mean counts of WBCs in the group of nine vaccinated cats. The
stippled squares with standard deviation represent the white cell
counts in the two mock-vaccinated cats (WBC counts for unvaccinated
cats were are similar for cats given standard RCNV in another study
not shown). The average of the total WBCs in peripheral blood samples
from the nine vaccinated cats and the two unvaccinated cats on the
challenge day were considered the normal WBCs.
throughout the experimental course. In contrast, the total
white cell counts of cats not vaccinated were less than
5 1 103/ml on Days 3 and 9 and were 2.2 1 103/ml on
Day 5. Thus, the unvaccinated cats clearly developed
panleukopenia, severe lymphopenia, and eosinopenia
following FPV challenge. As a typical course of feline
panleukopenia, unvaccinated cats had cell counts in the
normal range by Day 20 after challenge.FIG. 3. Geometric mean of FPV VN titers of sera of nine 5-month-
In conclusion, the results in this report show in vivoold specific-pathogen-free cats vaccinated and boosted subcutane-
ously with RCNV/FPV. Nine cats were subcutaneously vaccinated with and in vitro expression of FPV VP2 by a recombinant
1 1 107 PFU of RCNV/FPV and then boosted subcutaneously on Day RCNV/FPV. The recombinant induced a rapid, vigorous,
21. Two cats were mock-infected and boosted with PBS at the same FPV VN antibody response and the response protected
time as the vaccinated group. The 11 cats were challenged 13 days
cats against FPV challenge administered 13 days afterafter the booster. Serum samples were collected on Days 0, 21, 28,
a booster immunization. Of interest, studies on human34, 37, 39, 43, and 54 after the primary vaccination. The FPV VN test
procedures and antibody titer interpretations were done essentially as parvovirus B19 have indicated that B19 virus capsids
described previously (29). The reciprocal of the highest dilution of se- composed of only VP2 elicit weak neutralizing antibody
rum at which no FPV inclusion bodies were detected by microscopy activity and capsids containing both VP1 and VP2 induce
of infected cells was interpreted as the VN titer. The solid bars with
a strong VN antibody activity (30). Here we show thatindicated standard deviations represent VN responses of the vacci-
FPV VP2 alone is able to induce sufficient antibodiesnated group and the hatched bars with standard deviations represent
VN response of unvaccinated cats. protecting against FPV challenge.
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